Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for Lucid-MS, allowing the company to proceed directly into a Phase 2 clinical trial in people with multiple sclerosis. The announcement was highlighted in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach.”
The IND submission, approximately 15,000 pages in length, included a comprehensive package of pharmacology, toxicology, and manufacturing data. With the clearance, Quantum BioPharma can initiate a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate Lucid-MS in MS patients. Lucid-MS is a patented new chemical entity that has demonstrated in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
The FDA clearance represents a critical step for Quantum BioPharma, a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of its lead compound, Lucid-MS. This milestone opens the door to human testing, bringing a potential new therapy closer to patients who currently have limited treatment options for MS.
Beyond Lucid-MS, Quantum BioPharma has developed UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.). Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and holds royalty rights of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. More information about Unbuzzd is available at www.unbuzzd.com.
For investors, the latest news and updates relating to QNTM can be found in the company’s newsroom at https://nnw.fm/QNTM. The full press release is accessible at https://nnw.fm/E5nJp.
The FDA clearance is significant because it validates the extensive preclinical work conducted by Quantum BioPharma and allows the company to advance Lucid-MS into human trials. Multiple sclerosis is a chronic, often debilitating disease affecting millions worldwide, and current therapies primarily manage symptoms rather than reverse myelin damage. If Lucid-MS proves effective in clinical trials, it could represent a novel approach to treating MS by addressing the root cause of the disease. For the biotech industry, this milestone underscores the potential of micro-cap companies to achieve regulatory breakthroughs that larger firms may overlook. For patients and investors, it signals hope for a new treatment option and potential value creation.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, featured Quantum BioPharma in its audio press release. NetworkNewsWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The platform aims to connect private and public companies with investors, influencers, consumers, and journalists.
